EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB

Caryn M Upton iD, Jose M Calderin iD, Andreas H Diacon, Martin J Boeree, Paolo Denti iD, Lubbe Wiesner iD, Tracy Kellermann iD, Megan McCulloch, Rob Aarnoutse

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00931-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Caryn M Upton und 8 weiteren Autor:innen. Beteiligte Einrichtung: Radboud University Medical Center, Radboud Institute for Medical Innovation, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Cycloserine, Clofazimine, Antitubercular Agents, Isoxazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership, Radboudumc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculous meningitis (TBM) treatment outcomes are poor, partly due to suboptimal drug penetration into the cerebrospinal fluid (CSF). Little is known about the CSF pharmacokinetics of many TB drugs, both established and new. This study investigated the CSF penetration of cycloserine (administered as terizidone) and clofazimine, two core second-line drugs for drug-resistant tuberculosis (TB). We recruited participants with pulmonary drug-resistant TB, but without TBM, receiving terizidone and/or clofazimine for at least 2 weeks and collected serial plasma samples and a single CSF sample. Drug concentrations were quantified with validated liquid chromatography-tandem mass spectrometry methods. Pharmacokinetic parameters were determined using noncompartmental analysis, and population pharmacokinetic modeling was used to estimate the partition coefficient and equilibration half-life. Data were available from 27 participants, with a median age of 36 (range 20–60) and a weight of 52 kg (30–73 kg), who contributed 216 plasma and 27 CSF samples. The plasma pharmacokinetics of both drugs was in line with previous reports. Terizidone, measured as cycloserine, achieved CSF exposure of 69% relative to plasma, with plasma and CSF concentrations equilibrating with a half-life of 4.7 hours. Clofazimine CSF penetration was 0.13% of plasma exposure, with an equilibration half-life of 55.4 hours. Cycloserine and clofazimine concentrations in CSF approximated their estimated unbound (active) concentration in plasma, thus suggesting good penetration of the unbound drug into the CSF, supporting their potential use in TBM regimens. This study demonstrates a feasible and reproducible method for effective assessment of CSF drug penetration for CNS infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CycloserineClofazimineAntitubercular AgentsIsoxazolesTuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosis, MeningealHumansAdultMaleMiddle AgedFemaleYoung AdultTandem Mass SpectrometryHalf-LifeOxazolidinones

Stichwörter der Autor:innen

NONMEMcerebrospinal fluidclofaziminecycloserinepharmacokineticspopulation modelingpopulation pharmacokineticsterizidonetuberculous meningitis

Substanzen

CycloserineClofazimineAntitubercular AgentsterizidoneIsoxazolesOxazolidinones

Autor:innen und Institutionen

  • Radboud University Medical Center, Radboud Institute for Medical Innovation, Nijmegen, the Netherlands.
  • TASK, Cape Town, South Africa.
  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University, Stellenbosch, South Africa.

ORCID-Profile: Caryn M Upton, Jose M Calderin, Paolo Denti, Lubbe Wiesner, Tracy Kellermann

Förderung

  • European and Developing Countries Clinical Trials Partnership
  • Radboudumc

Zitieren

APA

Upton, C. M., Calderin, J. M., Diacon, A. H., Boeree, M. J., Denti, P., Wiesner, L., Kellermann, T., McCulloch, M., & Aarnoutse, R. (2025). Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00931-25

Vancouver

Upton CM, Calderin JM, Diacon AH, Boeree MJ, Denti P, Wiesner L, et al. Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00931-25

BibTeX
@article{Upton2025,
  author = {Upton, Caryn M and Calderin, Jose M and Diacon, Andreas H and Boeree, Martin J and Denti, Paolo and Wiesner, Lubbe and Kellermann, Tracy and McCulloch, Megan and Aarnoutse, Rob},
  title = {Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00931-25}
}
Kostenlos starten →